The FDA Advisory Committee Meeting scheduled for October 31 to review palovartoene capsules as a potential treatment for FOP has been postponed. This is NOT a unique situation and the postponement should not be viewed as a negative sign for the palovarotene program.
The meeting has been postponed to ensure that the most thorough and complete review of the data is completed. It also ensures that when they come together that the FDA is asking the right questions and maximizing the time that everyone (including the families providing testimony in the Open Public Hearing) is maximized.
Read the full announcement from the FDA
We will update you as soon as we know more. If you have any questions, they can be sent to [email protected].
Do you like this post?
